Bausch and Lomb Announces the U.S. Launch of LOTEMAX(R) SM (Loteprednol Etabonate Ophthalmic Gel) 0.38% for the Treatment of Postoperative Inflammation and Pain Following Ocular Surgery

Shipments to U.S. Pharmaceutical Distributors Begin BRIDGEWATER, N.J., April 2, 2019 -- (Healthcare Sales & Marketing Network) -- Bausch & Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TXS: ... Biopharmaceuticals, Ophthalmology, Surgery, Product Launch Bausch & Lomb, Bausch Health Companies, LOTEMAX, loteprednol etabonate
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news